Brief: Larimar Therapeutics Q2 Net Income USD -21.627 Million
Aug 07 (Reuters) - Larimar Therapeutics Q2 basic EPS USD -0.34. * Q2 operating expenses USD 24.599 million * Q2 income from operations USD -24.599 million
Recent news on Larimar Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
Larimar tumbles as safety concerns resurface in rare disease drug study update
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
U.S. STOCKS ON THE MOVE-SpaceX, Charter, Gulfport Energy
Larimar tumbles as safety concerns resurface in rare disease drug study update